Idiopathic pneumonia syndrome (IPS) is a rare complication following stem cell transplant (SCT) and its incidence among pediatric SCT recipients is not known. To assess the incidence of IPS, we retrospectively reviewed the incidence of IPS at our center. IPS is defined as the presence of multilobar infiltrates by chest radiograph or computed tomography scan, need for supplemental oxygenation with declining pulse oximetry and no identifiable pulmonary infection. Between July 1999 and August 2005, 11 of 93 children who received a fully ablative allogeneic SCT (11.8%) developed IPS. All 11 patients had normal pulmonary evaluation before transplant. IPS developed at a median of 17 days (range 8-42 days) after transplant. Recipients of unrelated donor transplant had increased risk of developing IPS. There was a significant association between acute or hyperacute graft-versus-host disease (GVHD) and IPS (P ¼ 0.035). All patients had significant hypoxia and five patients required assisted ventilation. IPS was the cause of death in two patients. Although there was complete resolution of respiratory symptoms in the other nine patients, overall transplant-related mortality was significantly higher among patients with IPS (64 vs 17%, P ¼ 0.002). IPS is a relatively common complication in pediatric SCT recipients and acute GVHD is an important associated factor. Bone Marrow Transplantation (2006) 38, 285-289. doi:10.1038/sj.bmt.1705436; published online 3 July 2006 Keywords: idiopathic; pneumonia; transplant; children
Background
Stem cell transplant (SCT) is an established therapy for various malignant and non-malignant disorders in children.
Despite significant improvement in supportive care, SCT continues to be associated with significant morbidity and mortality. Idiopathic pneumonia syndrome (IPS) is an important non-infectious post-transplantation lung injury occurring in recipients of allogeneic hematopoietic stem cell transplantation. Although the incidence of IPS has been estimated at 3-15% with conventional preparative regimens, 1-3 the mortality of IPS approaches 60% 4,5 despite improvements in infection prophylaxis and critical care management. 5 Although the specific etiology of IPS remains unclear, its mechanism includes cytokine-modulated immunological mechanisms during the acute and chronic phases after BMT leading to progressive, inflammatory and fibrotic lung disease. 6 The development of IPS may be related to pre-transplant radiation and the onset of acute graft-versus-host disease (GVHD). Indeed, the mean lung dose of radiation (49.4 Gy) is seen as an independent predictor of lethal pulmonary complications in patients receiving allogeneic BMT. 7 There are few case reports in the literature describing IPS in pediatric patients undergoing SCT. The incidence and clinical outcome of IPS following SCT in pediatric patients is not known. We report on the incidence and clinical outcome of IPS in children undergoing SCT at our center.
Materials and methods
The BMT database at Vanderbilt Children's Hospital contains prospectively collected data on all patients transplanted at our center. We screened database records on 93 patients receiving fully ablative allogeneic blood or marrow transplant between July 1999 and August 2005 for any pulmonary complications. For these patients, all available medical records, notes, correspondence and autopsy reports were reviewed to identify, in detail, the nature of the event and/or prior pulmonary disease or its evolution. Patients with clinically significant pulmonary complications were identified. An extensive chart review was performed to determine age, gender, underlying diagnosis, type of transplant, conditioning therapy, GVHD (prophylaxis, grade, treatment), infections, other clinical complications as well as the onset, evolution and clinical outcome of pulmonary complications.
As part of their pre-transplant evaluation, all patients had a chest X-ray and pulmonary function testing was obtained for patients older than 8 years of age. IPS was defined as the presence of multilobar infiltrates by chest X-ray or computed tomography (CT) scan. Signs and symptoms of pneumonia with abnormal pulmonary physiology, including the need for supplemental oxygenation with declining pulse oximetry values, determined the onset day of IPS. The absence of active lower respiratory tract infection was determined by bronchoalveolar lavage (BAL), lung biopsy or autopsy. Patients with symptoms of fluid overload that responded to diuretics were not categorized as having IPS. Patients without BAL that responded quickly to anti-microbial agents were not categorized as having IPS.
Statistical analyses
Relationships between the risk of IPS and dichotomous variables of interest were assessed using log-transformed odds ratios with continuity correction. Kaplan-Meier survival curves were used for graphical presentation of time to death. Cox's proportional hazard regression model was used to obtain hazard ratios of death. The limited number of events (all-cause mortality) allowed us to include only the following three covariates: IPS, GVHD and type of transplant (related vs unrelated). Assumptions of proportional hazard for the final model were evaluated by examining interactions between time and each variable in the model.
The Institutional Review Board of Vanderbilt University Medical Center approved the retrospective review of patients' medical records.
Results
Of the 93 patients receiving allogeneic SCT, 18 patients had signs of pulmonary disease; two patients had pulmonary edema, six patients had infection-related pneumonitis and 11 patients met the criteria for IPS for an overall incidence of 11.8%. The characteristics of patients with and without IPS are summarized in Table 1 . The median age was 8 years (range 0.6-20 years); six were female and five were male. Underlying diagnoses consisted of acute lymphocytic leukemia (n ¼ 6), myelodysplastic syndrome (n ¼ 2), acute myelogenous leukemia, chronic myelogenous leukemia and Hurler syndrome (one each). All patients had normal chest X-ray and five patients had pre-transplant pulmonary function tests that were normal. Conditioning regimens consisted of chemotherapy alone in four patients and cyclophosphamide plus total body irradiation (TBI) (1320-1440 cGy) in seven patients. Two patients had prior radiation exposure: patient 1 had previous TBI (1320) cGy for a transplant a year before this transplant and patient 9 had previous whole abdominal and pelvic irradiation (2100 cGy) for neuroblastoma. Ten of the 11 patients received the transplant from unrelated donors (seven bone marrow and three cord blood) and one had a matched related donor. All allogeneic transplants were non-T-cell depleted, three of the seven unrelated marrow grafts were mismatched and all cord blood units were mismatched at one or two antigens (Table 2) . GVHD prophylaxis consisted of cyclosporine and methotrexate in all allogeneic transplants, except for recipients of cord blood who received cyclosporine and prednisone. Grade II-IV acute GVHD developed in 39% of recipient of related donor transplant compared to 67% of those receiving unrelated donor transplant.
The diagnosis of IPS was made between 8 and 42 days (median 17) post transplant. All patients had significant hypoxia; four patients required mechanical ventilation and one patient required positive airway pressure. Significant pulmonary disease was present on chest X-ray or computer tomography. All patients had associated acute GVHD (n ¼ 9) or hyperacute GVHD (n ¼ 2) occurring simultaneously or within 48 h preceding the onset of IPS. The incidence of acute GVHD was 100% in patients with IPS compared to 51% in the group without IPS (P ¼ 0.035). Recipients of unrelated donor transplant had a trend toward increased risk of IPS compared to recipients of matched related donors (P ¼ 0.09). All patients received 2 mg/kg/day of steroid therapy, except for patients 3 and 9. Those patients steroid dose was increased from 2 mg/kg/day (used for GVHD prophylaxis) to 4 mg/ kg/day. If patients' symptoms worsened, they received infliximab (Remicade, Centocor, Malvern, PA, USA) 10 mg/kg/dose intravenously for 4 weekly doses (patients 3 and 6) or etanercept (Enbrel; Immunex, Seattle, WA, USA) 0.4 mg/kg (maximum dose 25 mg) subcutaneously twice a week for a total of eight doses. Of the five patients who required assisted ventilation, three recovered and two died as a complication of IPS. All the patients who did not require assisted ventilation had resolution of their respiratory symptoms and X-ray findings at a median of 8.5 days (range 5-28 days). Patients with IPS had significantly higher transplant-related mortality as compared to the patients who did not have IPS (64 vs 17%, P ¼ 0.002). Although 81% of patients (nine of 11 patients) had complete resolution of respiratory symptoms, the overall survival of those patients was significantly worse than patients without IPS (P ¼ 0.005), even after adjusting for donor type and GVHD ( Figure 1 ). The cause of death for patients who recovered was complications related to GVHD (n ¼ 5) and relapse (n ¼ 1).
Discussion
An NIH panel defined IPS as widespread alveolar injury following SCT not attributed to an active lower respiratory tract infection nor cardiogenic cause. 8 Evidence of widespread lung injury was defined as multilobar infiltrates on chest radiograph or CT, clinical signs of pneumonia and abnormal pulmonary physiology, such as an increased alveolar to arterial oxygen gradient or new restrictive lung findings. The absence of lower respiratory tract infection was determined by BAL negative for both bacterial and non-bacterial pathogens, transbronchial lung biopsy and a confirmatory negative test for infection 2-14 days postinitial procedure.
Review of the literature reveals the reported incidence of IPS after myeloablative conditioning to be 3-15%. 3, [9] [10] [11] [12] [13] [14] Time of onset was initially reported at between 6 and 7 weeks post infusion of stem cells, 8 with more recent studies reporting an even earlier onset. 13, 14 A recent study from the Seattle group reported that the median time to onset of IPS was 22 days after fully myeloablative regimen and 16 days after non-myeloablative regimen, reflecting the use of bone marrow vs peripheral blood stem cells as the stem cell source. This is similar to our observation of a median onset of 17 days. The clinical course, however, of rapid onset of respiratory failure and up to 80% mortality has remained unchanged. 3, 5, [15] [16] [17] Patients requiring mechanical ventilation are expected to have an even greater mortality rate. In our center, the overall survival of 27% was significantly worse than what was observed in patients without IPS.
The goal of this study was to review the incidence of clinically significant IPS in pediatric patients following SCT. The incidence of 11.8% at our institution is similar to that observed in adult patients. 1, 10, 11, 16, 18 There are few reported pediatric cases of IPS in the literature. A pediatric case series (three patients) from the University of Michigan had the onset of IPS from day 8 to 55 post transplant.
14 In a recent report on pulmonary complications in 138 children from Germany, three patients were reported to have IPS. All three cases developed symptoms more than 6 months post transplant and two cases had associated viral infections. 19 A number of risk factors have been identified as contributing to the development of IPS, including age 440 years, myeloablative regimens, 13, 17 acute GVHD 3, 16, 20 and the use of high-dose TBI. 7, 13 In our cohort of patients, the conditioning regimen consisted of chemotherapy alone in four patients and TBI with chemotherapy in seven patients. Unfortunately, our patient sample is too small to draw any meaningful conclusions regarding the impact of conditioning and the dose of TBI on the development of IPS. In our study, recipients of unrelated donor transplant had an increased risk of developing IPS, although it did not reach statistical significance owing to small sample size. The only consistent observation in our patients was the association of acute GVHD and the development of IPS, following the administration of non-T-cell-depleted marrow or cord blood. These clinical data support the murine transplant models that suggest that the lung is susceptible to the combined effect of radiation conditioning and alloreactive T cells. 6, 21 Murine data suggest that the pathogenesis of acute lung injury following GVHD may be the result of two pathways of immune-mediated injury following allogeneic SCT, a T-cell axis and an inflammatory cytokine axis. [22] [23] [24] [25] [26] In brief, the SCT conditioning process causes the release of tumor necrosis factor (TNF)a and interleukin (IL)-1 that increases the ability of host antigen-presenting cells to present alloantigens to mature donor T cells, thus upregulating chemokine expression in the lung. Donor T cells are activated and secrete interferong (which primes donor macrophages and monocytes) and IL-2 (which facilitates T-cell activation and generation of lymphocyte effectors, such as Th-1).
Treatment for IPS has focused on supportive care measures that include mechanical ventilation, initiation of broad-spectrum antibiotics and suppression of the inflammatory response with steroids. There are no prospective studies on the treatment of IPS. However, given the preclinical data and murine models, the University of Michigan reported on three pediatric patients who received etanercept (a dimeric protein consisting of two soluble p75 TNF receptors fused to the Fc portion of a type I immunoglobulin molecule). All three patients demonstrated significant improvement in radiographic lung findings and pulmonary function.
14 However, all patients died between days 89 and 116 post transplant. An additional 15 patients were treated by the same group with preliminary reported survival at 56 days of 60%. 25, 27 We treated all our patients with steroid therapy and the five patients who experienced worsening of their respiratory symptoms (increasing hypoxia or increased ventilator support) despite therapy with steroids received either etanercept or infliximab therapy. All six patients who did not require assisted ventilation had resolution of their hypoxia and respiratory symptoms. Three of the five patients who required assisted ventilation had complete resolution of their pulmonary disease. Despite an 81% response rate to therapy, the overall survival of these patients was poor. Prompt intervention with immunosuppressive agents seems to ameliorate symptoms of IPS, but does not impact overall survival. The development of IPS early post transplant seems to be a marker of more severe GVHD and a predictor of poor outcome. It might be reasonable to either try a more intensive immune suppression or novel agents early in the course of IPS to see if that will impact the overall poor survival of those patients. A phase II study is being initiated by the Children Oncology Group to evaluate the efficacy of etanercept in children with IPS.
IPS is not infrequent among pediatric patients undergoing allogeneic SCT. There is clear association between IPS and acute GVHD. Despite early response to immune suppression, the overall survival remains poor.
